These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 9847972)
1. The treatment of Parkinson's disease: current concepts and rationale. Hingtgen CM; Siemers E Compr Ther; 1998; 24(11-12):560-6. PubMed ID: 9847972 [TBL] [Abstract][Full Text] [Related]
2. Treatment options for early Parkinson's disease. Stacy M; Brownlee HJ Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572 [TBL] [Abstract][Full Text] [Related]
3. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
5. Treatment of Parkinson's disease. From theory to practice. Ahlskog JE Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048 [TBL] [Abstract][Full Text] [Related]
6. Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263 [TBL] [Abstract][Full Text] [Related]
7. [Drug therapy of Parkinson disease]. Dietrichs E Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089 [TBL] [Abstract][Full Text] [Related]
8. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
12. Management of Parkinson's disease a review of current and new therapies. Mendis T; Suchowersky O; Lang A; Gauthier S Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867 [TBL] [Abstract][Full Text] [Related]
13. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. During MJ; Kaplitt MG; Stern MB; Eidelberg D Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246 [TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2004 Jun; (11):1736-54. PubMed ID: 15652077 [No Abstract] [Full Text] [Related]
15. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A; Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107 [TBL] [Abstract][Full Text] [Related]
18. Recent progress in the treatment of Parkinson's disease. Siemers E Compr Ther; 1992 Sep; 18(9):20-4. PubMed ID: 1358500 [TBL] [Abstract][Full Text] [Related]
19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
20. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? Clarke CE Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]